Venlafaxine exposure in pregnancy, a multicenter ENTIS study

First published: 15/10/2012

Last updated: 19/04/2021





Administrative details

EU PAS number
EUPAS3057
Study ID
40624
DARWIN EU® study
No
Study countries
Finland
France
Israel
Italy
Netherlands
Switzerland

Study description

Introduction Venlafaxine (Efexor®) is a serotonin and noradrenaline reuptake inhibitor (SNRI) used for the treatment of depression and anxiety disorders. The limited data on the use of venlafaxine in human pregnancy do not indicate an increased risk of congenital malformations. The main purpose of the study is to assess the rate of major malformations after first trimester exposure to venlafaxine. Methods This multicenter, prospective cohort study was performed using data from eight centers who are member of the European Network of Teratology Information Services (ENTIS). Data on pregnancy and pregnancy outcome of women who used venlafaxine in pregnancy were collected during individual risk counseling. Standardized procedures for data collection and follow-up were used by each center.

Study status

Ongoing

Research institutions and networks

Institutions



Teratology Information Service, Helsinki (TIS Helsinki), HUSLAB Finland First published: 09/04/2010 Last updated: 16/08/2011 Institution Outdated Educational Institution Hospital/Clinic/Other health care facility ENCEPP partner

Swiss Teratogen Information Service

First published: 01/02/2024

Last updated: 01/02/2024

Institution

Centre de Référence sur les Agents Tératogènes (CRAT) Paris, France, Florence Teratology Information Service, Careggi university hospital Florence, Italy, CEPIG, Genetica Clinica, Azienda Ospedaliera Padov Padova, Italy, Poison Control Centre and Teratology Information Service, Ospedali Bergamo, Italy, Swiss Teratogen Information Service and Division of clinical
Pharmacology and Toxicology, University Hospital,
Lausanne Lausanne, Switserland, BELTIS Rabin.
Medical. Center Petah-Tikva Affiliated with the
Sackler School of Medicine, Tel Aviv University Tel
Aviv, Israel, Telefono Rosso, Catholic University of
Sacred Heart Rome, Italy

Networks

European Network of Teratology Information
Services (ENTIS)
Austria
Czechia
Finland
France
Germany
Greece
Italy
☐ Netherlands
Spain
Switzerland
United Kingdom
First published: 31/05/2010

Last updated: 13/05/2024



ENCePP partner

Contact details

Study institution contact

Bernke te Winkel b.tewinkel@lareb.nl

Study contact

b.tewinkel@lareb.nl

Primary lead investigator

Bernke te Winkel

Primary lead investigator

Study timelines

Date when funding contract was signed

Actual: 30/09/2008

Study start date

Actual: 27/10/2008

Date of final study report

Planned: 28/12/2021

Sources of funding

More details on funding

Ministery of Health, The Netherlands

Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type

Study type list

Study type:

Non-interventional study

Scope of the study:

Assessment of risk minimisation measure implementation or effectiveness

Main study objective:

To assess the risk of venlafaxine exposure in early pregancy

Study Design

Non-interventional study design

Cohort

Study drug and medical condition

Study drug International non-proprietary name (INN) or common name VENLAFAXINE

Population studied

Age groups

Preterm newborn infants (0 - 27 days)

Term newborn infants (0 - 27 days)

Adults (18 to < 46 years)

Special population of interest

Pregnant women

Estimated number of subjects

1300

Study design details

Outcomes

Rate of major birth defects after first trimester exposure, rate of spontaneous abortionrate of prematurity birth weight postnatal disorders

Data analysis plan

Birth defect rates include live births and anomalies in elective terminations of pregnancies (ETOPs) and miscarriages. For calculating rates of major birth defects possibly associated with a teratogen, welldefined genetic syndromes are excluded. See: Schaefer C, Ornoy A, Clementi M, Meister R, Weber-Schoendorfer C. Using observational cohort data for studying drug effects on pregnancy outcome--methodological considerations. Reprod Toxicol. 2008,26:36-41. For calculation spontaneous abortion rate see Meister R, Schaefer C. Statistical methods for estimating the probability of spontaneous abortion in observational studies--analyzing pregnancies exposed to coumarin derivatives. Reprod Toxicol. 2008,26:31-5

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025.

The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data sources (types)

Other

Data sources (types), other

ENTIS provides drug risk assessment for pregnant patients and/or physicians.

Exposed pregnancies are documented and after the expected date of delivery,

follow-up is conducted both using a structured questionaire or phone interview. See Schaefer C et al, Reproductive Toxicology 2008, 26, 36-41

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No